BioCryst Submits NDA For Hereditary Angioedema Candidate
Zacks Investment Research | Dec 12, 2019 02:34AM ET
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that it has submitted a new drug application (NDA) to the FDA seeking approval of berotralstat (BCX7353), an oral once-daily treatment for the prevention of hereditary angioedema (HAE) attacks.
The company plans to submit marketing authorization application (MAA) for BCX7353 to prevent HAE attacks in the EU and Japan during the first quarter of 2020.
In November 2019, BioCryst out-licensed its commercialization rights to BCX7353 in Japan to Torii Pharmaceutical. Per the company, Torii will be solely responsible for the commercialization activities of BCX7353 to prevent HAE attacks in Japan.
HAE is a rare, genetic and potentially life-threatening disorder that can cause recurrent attacks of edema (swelling) in various parts of the body.
Shares of BioCryst have plunged 65.8% so far this year against the industry’s increase of 11.1%.
We would like to remind investors that in May 2019, BioCryst announced that the phase III APeX-2 study, which evaluated both dose levels of BCX7353 (110 mg and 150 mg) for the prevention of HAE attacks, met the primary endpoint with the higher dose reducing HAE attacks in patients by 44% as compared to placebo.
Data from the study showed that patients with less than two HAE attacks per month experienced a 66% reduction in the attacks when administered with 150 mg of BCX7353. While for patients suffering more than two attacks per month experienced 40% reduction in attacks under the same dose.
BioCryst plans to begin a phase III ZENITH-2 study on oral BCX7353 (750 mg) for the treatment of acute HAE attacks in 2020.
Zacks Rank & Stocks to Consider
BioCryst currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Anika Therapeutics Inc. (NASDAQ:ANIK) , Guardant Health, Inc. (NASDAQ:GH) and Innoviva, Inc. (NASDAQ:INVA) , all sporting a Zacks Rank #1 (Strong Buy). You can see .
Anika’s earnings estimates have moved 16% north for 2019 and 17.4% for 2020 over the past 60 days. The stock has soared 61.4% year to date.
Guardant Health’s loss per share estimates have narrowed 30.7% for 2019 and 8.5% for 2020 over the past 60 days. The stock has soared 88.3% so far this year.
Innoviva’s earnings estimates have been revised 18.7% upward for 2019 and 25.2% for 2020 over the past 60 days.
Get The News You Want
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.